Immunome Inc Stock Price, News & Analysis

Immunome (Nasdaq: IMNM), a biotechnology company developing targeted cancer therapies, has granted inducement stock options to 5 new employees under its 2024 Inducement Plan. The Compensation Committee approved options to purchase 39,000 shares of common stock at an exercise price of $10.59 per share.

The stock options will vest over a four-year period, with 25% vesting after one year and the remaining balance vesting monthly over the following 36 months, contingent on continued employment.

Immunome (Nasdaq: IMNM), a biotechnology company specializing in targeted cancer therapies, announced inducement grants to 8 new employees under its 2024 Inducement Plan. The Compensation Committee approved non-statutory stock options to purchase 125,500 shares of common stock at an exercise price of $8.47 per share.

The stock options will vest over a four-year period, with 25% vesting after one year and the remaining balance vesting monthly over the following 36 months, contingent on continued employment.

Immunome (NASDAQ: IMNM), a biotechnology company specializing in targeted cancer therapies, announced the granting of inducement awards to 13 new employees. The Compensation Committee approved non-statutory stock options to purchase 173,000 shares of common stock under the 2024 Inducement Plan, in accordance with Nasdaq Listing Rule 5635(c)(4). The stock options have an exercise price of $9.06 per share, based on the closing price on June 2, 2025. The options will vest over four years, with 25% vesting after one year and the remaining balance vesting monthly over 36 months, contingent on continued employment.

Immunome (NASDAQ: IMNM), a biotechnology company specializing in targeted cancer therapies, has announced its participation in two upcoming investor conferences. The company will present at the TD Cowen 6th Annual Oncology Innovation Summit on May 27, 2025, from 6:30 AM to 7:00 AM PT, and at the Goldman Sachs 46th Annual Global Healthcare Conference on June 10, 2025, from 11:00 AM to 11:35 AM PT. Live webcasts and 30-day replay links for both presentations will be accessible through the events section of Immunome's investor website.

Immunome (NASDAQ: IMNM) reported its Q1 2025 financial results and provided updates on its cancer therapy pipeline. The company's cash position stood at $317.3 million, including $161.7 million from January 2025 financing, expected to fund operations into 2027. Q1 2025 resulted in a net loss of $41.6 million, with R&D expenses of $36.9 million and G&A expenses of $10.7 million.

Key pipeline updates include: completion of enrollment for Phase 3 RINGSIDE Part B study of varegacestat for desmoid tumors, with topline data expected in H2 2025; ongoing Phase 1 trial of IM-1021 (ROR1 ADC) in solid tumors and lymphoma; IND clearance for IM-3050 (FAP radiotherapy) with clinical trial expected in H2 2025; and continued IND-enabling work for three preclinical ADCs (IM-1617, IM-1335, and IM-1340) incorporating HC74 technology.

Immunome (NASDAQ: IMNM), a biotechnology company specializing in targeted cancer therapies, announced inducement grants to nine new employees on May 1, 2025. The Compensation Committee approved non-statutory stock options to purchase 164,500 shares of common stock under the Company's 2024 Inducement Plan.

The stock options have an exercise price of $8.86 per share, matching the company's closing price on May 1, 2025. The options will vest over four years, with 25% vesting after one year and the remaining balance vesting monthly over 36 months, contingent on continued employment.

Immunome (Nasdaq: IMNM), a biotechnology company specializing in targeted cancer therapies, has announced its upcoming participation in the 24th Annual Needham Virtual Healthcare Conference. The company's management will engage in a fireside chat scheduled for Thursday, April 10, 2025, at 12:45 p.m. Eastern Time.

The presentation will be accessible through a live audio webcast available on the Investor Relations section of Immunome's website. Following the live presentation, a replay will remain available for approximately 30 days.

Immunome (Nasdaq: IMNM), a biotechnology company developing targeted cancer therapies, has announced the granting of inducement awards to five new employees. The awards, approved by the Compensation Committee on April 1, 2025, consist of non-statutory stock options to purchase a total of 228,000 shares of common stock under the company's 2024 Inducement Plan.

The stock options have an exercise price of $6.26 per share, matching Immunome's closing price on April 1, 2025. These options will vest over a four-year period, with 25% vesting after one year and the remaining balance vesting monthly over the subsequent 36 months, contingent on continued employment.

Immunome (NASDAQ: IMNM) announced its full year 2024 financial results and business updates. The company expects topline data from the Phase 3 RINGSIDE study of varegacestat for desmoid tumors in H2 2025. Key developments include the first patient dosing in Phase 1 trial of IM-1021 (ROR1-targeted ADC) and IND submission for IM-3050 (FAP-targeted radioligand therapy).

Financial highlights: Cash position of $217.3 million as of December 31, 2024, plus additional $172.5 million from January 2025 financing. The company reported R&D expenses of $129.5M, in-process R&D expenses of $152.3M, and G&A expenses of $33.0M for 2024. Net loss was $293.0M. Cash runway extends into 2027.

Pipeline progress includes three novel ADCs (IM-1617, IM-1340, IM-1335) in IND-enabling manufacturing and completion of RINGSIDE Part B enrollment in February 2024.